Barclays Downgrades Enanta Pharmaceuticals (ENTA) to Underweight
Tweet
Share
E-mailGet Alerts ENTA Hot Sheet
Price: $13.47 --0%
Rating Summary:
15 Buy, 3 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 5 | Down: 4 | New: 44
Rating Summary:
15 Buy, 3 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 5 | Down: 4 | New: 44
Join SI Premium – FREE
Barclays downgraded Enanta Pharmaceuticals (NASDAQ: ENTA) from Equalweight to Underweight with a price target of $16.00 (from $45.00).
For an analyst ratings summary and ratings history on Enanta Pharmaceuticals click here. For more ratings news on Enanta Pharmaceuticals click here.
Shares of Enanta Pharmaceuticals closed at $23.90 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Barclays Downgrades Unite Group (UTG:LN) to Underweight
- Barclays Upgrades Segro PLC (SGRO:LN) (SEGXF) to Equalweight
- DocMorris AG (DOCM:SW) PT Raised to CHF12.50 at Deutsche Bank
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesRelated Entities
BarclaysSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
